Core Viewpoint - The article discusses the termination of the exclusive distribution rights of AestheFill products held by Dato Medical, a subsidiary of *ST Suwu, by REGEN Biotech, a subsidiary of Aimeike, due to alleged breaches of contract. This move is expected to significantly impact *ST Suwu's medical aesthetics business revenue and profits in the second half of 2025 [6][10][18]. Summary by Sections Company Actions - Aimeike's subsidiary REGEN sent a termination notice to Dato Medical on July 18, 2025, to revoke its exclusive distribution rights for AestheFill products in mainland China [6][12]. - The termination is based on Dato Medical's alleged transfer of its exclusive distribution business to its parent company, Jiangsu Wuzhong Meisheng Biotechnology Co., Ltd., which violates the agreement [21][22]. Financial Impact - In 2024, AestheFill contributed revenue of 326 million yuan, accounting for 20.42% of *ST Suwu's total revenue, with a gross profit of 269 million yuan, representing 34.80% of the company's gross profit [10][18]. - In the first quarter of 2025, AestheFill generated revenue of 113 million yuan, making up 35.55% of *ST Suwu's revenue, with a gross profit of approximately 92.44 million yuan, which is 45.77% of the company's gross profit [10][18]. Legal and Regulatory Context - *ST Suwu has denied any breach of contract and plans to take legal action to protect its rights [10][19]. - The company has faced regulatory scrutiny, including a notice from the China Securities Regulatory Commission regarding violations of securities laws, which could lead to severe penalties and potential delisting risks [24][25].